Researchers have developed a peripheral blood mRNA prognostic model that predicts the progression to metastatic castration-resistant prostate cancer, identifying SLC6A8 as a critical glycolysis-promoting biomarker that drives tumor proliferation and offers a novel framework for precision risk stratification.
A newly formulated transcriptomic signature derived from patient blood samples could soon change how physicians approach metastatic hormone-sensitive prostate cancer. By analyzing gene expression profiles from 147 patients who completed follow-up out of a 230-patient screening pool between February 1, 2024, and February 1, 2025, investigators at Sichuan Cancer Hospital and Institute isolated a reliable 3-gene panel. This molecular tool aims to flag patients at high risk of treatment resistance before standard clinical indicators register the shift.
In Plain English: The Clinical Takeaway
- Precision Blood Test: The newly identified mRNA signature analyzes a simple peripheral blood draw to evaluate molecular markers associated with aggressive prostate cancer behavior.
- Targeting Metabolism: The biomarker SLC6A8 regulates cellular energy production; inhibiting it has been shown in laboratory models to starve cancer cells and prompt programmed cell death.
- Personalized Treatment Timing: The model could soon help clinicians decide whether to escalate therapy early in patients with borderline clinical risk, or safely omit intensive chemotherapy in favorable molecular phenotypes.
Transcriptomic Discovery and the 3-Gene Signature Model
The investigation began with single-cell transcriptomic data from the GSE288878 data set to pinpoint genes linked specifically to metastatic castration-resistant prostate cancer (CRPC). Following this computational mapping, Shengke Yang and coinvestigators at Sichuan Cancer Hospital performed transcriptome sequencing on peripheral blood samples drawn from a prospective cohort. Out of 230 patients screened, 157 met eligibility criteria—requiring de novo metastatic hormone-sensitive prostate cancer (HSPC), at least one measurable lesion per RECIST 1.1 guidelines, and an ECOG performance status of 2 or lower—and were randomly split in a 7:3 ratio into development and validation cohorts.
Intersecting differentially expressed genes from the patient cohort with single-cell datasets yielded five candidate genes: SLC25A39, GRB10, SELENBP1, SLC6A8, and YBX3. From this group, elastic net-regularized Cox regression narrowed the selection down to the final three predictive genes. At a median follow-up of 611 days, with a 95% confidence interval ranging from 560 to 641 days, 54 enrolled patients experienced disease progression to metastatic CRPC. When researchers cross-referenced these findings with The Cancer Genome Atlas prostate cancer dataset encompassing 498 patients, elevated expression of SLC6A8 in tumor tissue emerged as an independent risk factor associated with shorter progression-free survival.
Mechanistic Insights Into SLC6A8 Inhibition and Glycolysis
To understand the biological mechanism driving this risk, the research team examined the downstream effects of the identified biomarker in C4-2B castration-resistant prostate cancer cells. SLC6A8 functions as a key transporter influencing cellular metabolism. When investigators applied the targeted inhibitor ompenaclid to these cancer cells, the drug suppressed cellular proliferation and actively promoted apoptosis, defined as programmed cell death.
Furthermore, pharmacological inhibition of SLC6A8 downregulated several key glycolysis-associated genes, including HK2, PFKP, and ALDH1B1. This metabolic suppression successfully reduced critical glycolytic metabolites such as lactic acid, pyruvic acid, and fructose-1,6-bisphosphate. By starving the cancer cells of the energy substrates they require for rapid division, the intervention disrupted the metabolic pathways that typically allow tumors to survive androgen deprivation therapy.
| Study Parameter | Clinical Metric / Value |
|---|---|
| Screening & Enrollment | 230 screened; 157 enrolled (Feb 1, 2024 – Feb 1, 2025) |
| Completed Follow-Up | 147 patients (103 development cohort, 44 validation cohort) |
| Primary Endpoint | Metastatic CRPC–free survival |
| Median Follow-Up Duration | 611 days (95% CI, 560–641) |
| Documented Progressions | 54 patients progressed to metastatic CRPC |
| Key Biomarker Identified | SLC6A8 (glycolysis-promoting biomarker) |
Translating Molecular Risk Stratification Into Clinical Decisions
The clinical implications of this blood-based model address a persistent gray area in urological oncology. For patients whose standard clinical risk remains equivocal—such as individuals presenting with oligometastatic bone disease or borderline prostate-specific antigen (PSA) levels—the transcriptomic signature could justify treatment intensification. This might include early combination therapy with triplet regimens or metastasis-directed radiotherapy before widespread radiographic progression occurs.
Conversely, patients presenting with high-volume disease who exhibit a favorable molecular signature may be candidates for de-escalation strategies, such as omitting docetaxel chemotherapy. Additionally, the signature offers a tool to enrich clinical trials by selecting patient populations with aggressive molecular phenotypes. The study authors emphasized that these applications remain hypothetical pending prospective validation.
Contraindications & When to Consult a Doctor
Patients undergoing treatment for metastatic prostate cancer should note that this peripheral mRNA model remains an investigational tool and is not yet deployed for routine clinical diagnosis or therapeutic decision-making outside of clinical studies. Individuals experiencing rising PSA levels, new bone pain, urinary obstruction, or constitutional symptoms should consult their medical oncologist immediately. Standard therapeutic regimens, including androgen receptor pathway inhibitors and androgen deprivation therapy, must not be altered based on experimental biomarkers without direct physician oversight.
Limitations and the Path Toward Multicenter Validation
Despite the translational potential of the 3-gene model, several methodological limitations temper its immediate clinical adoption. The current study relied on a single-center design evaluating an exclusively East Asian population, which restricts the immediate generalizability of the findings to broader, globally diverse patient demographics. Additionally, the trial lacked an external validation dataset, featured a small validation cohort with limited events that generated wide confidence intervals, and maintained a follow-up duration sufficient only for 1-year and 1.5-year projections.
On the mechanistic side, observations regarding the inhibitor ompenaclid were limited to a single cell line. To address these gaps, investigators are planning a prospective multicenter validation study across three to five tertiary medical centers in China.
References
- Li S, Zhou H, Wu Y, et al. Peripheral blood mRNA-based prognostic model for progression to metastatic castration-resistant prostate cancer and identification of SLC6A8 as a glycolysis-promoting biomarker. Front Oncol. Published online October 14, 2026. doi:10.3389/fonc.2026.1942820
- Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-360. doi:10.1056/NEJMoa1704174
- Saskia diagnosed with severe vitamin D deficiency
- Scientists Discover How Gut Bacteria Toxin Triggers Colon Cancer-And How to Block It
- Study Finds No Link Between COVID-19 Vaccines and Increased Cancer Risk in 36 Million Koreans (world-today-journal.com)
- CWZ Nijmegen draws attention to prostate and testicular cancer in November (archynewsy.com)
